Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Marksans PharmaBOM:524404 +3.12%80 Return-on-Tangible-Asset is 17.00% as of Jun. 2026, which is 27% above its 10-year median of 13.41. GuruFocus rates BOM:524404 with a GF Score™ of 80/100 and a GF Value™ of ₹253.38 (Significantly Overvalued). The stock has 6 warning signs investors should review. Among 1,007 Drug Manufacturers companies, Marksans Pharma ranks better than 88.88% on this metric.
Return-on-Tangible-Asset is calculated as Net Income divided by its average total tangible assets. Total tangible assets equals to Total Assets minus Intangible Assets. Marksans Pharma's annualizedNet Income for the quarter that ended in Jun. 2026 was ₹6,287 Mil. Marksans Pharma's average total tangible assets for the quarter that ended in Jun. 2026 was ₹36,989 Mil. Therefore, Marksans Pharma's annualized Return-on-Tangible-Asset for the quarter that ended in Jun. 2026 was 17.00%.
The historical rank and industry rank for Marksans Pharma's Return-on-Tangible-Asset or its related term are showing as below:
BOM:524404'
s Return-on-Tangible-Asset Range Over the Past 10 Years
Min: 1.4 Med: 13.41 Max: 23.95
Current: 15.3
During the past 13 years, Marksans Pharma's highest Return-on-Tangible-Asset was 23.95%. The lowest was 1.40%. And the median was 13.41%.
BOM:524404's Return-on-Tangible-Asset is ranked better than 88.88% of 1007
companies
in the Drug Manufacturers industry
Industry Median: 2.79
vs BOM:524404: 15.30
Return-on-Tangible-Asset measures the rate of return on the average total tangible assets (total assets minus intangible assets). Tangible means physical in nature. Intangible Assets are assets that are not physical in nature, and typically "derive their value from legal or intellectual rights." Return-on-Tangible-Asset measures a firm's efficiency at generating profits from its tangible assets. It shows how well a company uses what it has to generate earnings. Return-on-Tangible-Assets can vary drastically across industries. Therefore, Return-on-Tangible-Asset should not be used to compare companies in different industries.
Be Aware
Like ROE and ROA, Return-on-Tangible-Asset is calculated with only 12 months data. Fluctuations in the companys earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. Return-on-Tangible-Asset can be affected by events such as stock buyback or issuance, and by a companys tax rate and its interest payment. Return-on-Tangible-Asset may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).
Many analysts argue the higher return the better. Buffett states that really high Return-on-Tangible-Asset may indicate vulnerability in the durability of the competitive advantage.
Marksans Pharma Return-on-Tangible-Asset Related Terms
Marksans Pharma Return-on-Tangible-Asset Historical Data
* Premium members only.
The historical data trend for Marksans Pharma's Return-on-Tangible-Asset can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BOM:524404 vs LLY, JNJ, ABBV: Return-on-Tangible-Asset Comparison
For the Drug Manufacturers - General subindustry, Marksans Pharma's Return-on-Tangible-Asset, along with its competitors' market caps and Return-on-Tangible-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Marksans Pharma Return-on-Tangible-Asset vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Marksans Pharma's Return-on-Tangible-Asset distribution charts can be found below:
* The bar in red indicates where Marksans Pharma's Return-on-Tangible-Asset falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Asset, the net income of the last fiscal year and the average total tangible assets over the fiscal year are used. In calculating the quarterly data,
the Net Income data used here is four times the quarterly (Jun. 2026) net income data.
What does a Return-on-Tangible-Asset of 17.00% mean?
Marksans Pharma (BOM:524404) has a Return-on-Tangible-Asset of 17.00% as of Jun. 2026. Return on tangible assets is the ratio of current-period net income to average two-period tangible assets. View historical data on Marksans Pharma and its competitors. This is 27% above median its historical median of 13.41. Over the past decade, Marksans Pharma's Return-on-Tangible-Asset has ranged from 1.40 to 23.95. According to the industry distribution chart, Marksans Pharma ranks #112 out of 1007 companies in the Drug Manufacturers industry, placing it in the top 11.1%.
Is Marksans Pharma's Return-on-Tangible-Asset too high?
Marksans Pharma's current Return-on-Tangible-Asset of 17.00% is 27% above median its 10-year median of 13.41. Over the past 10 years, this metric has ranged from a low of 1.40 to a high of 23.95. The Drug Manufacturers industry median Return-on-Tangible-Asset is 2.79. Marksans Pharma's value of 17.00% is 509.3% above this industry median. Based on the distribution chart, Marksans Pharma ranks #112 out of 1007 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Marksans Pharma has a GF Score™ of 80/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Marksans Pharma's Return-on-Tangible-Asset compare to LLY and JNJ?
According to the Drug Manufacturers industry distribution chart, Marksans Pharma ranks #112 out of 1007 companies for Return-on-Tangible-Asset. This places Marksans Pharma in the top 11% of its industry — outperforming the majority of peers. The industry median Return-on-Tangible-Asset is 2.79. Marksans Pharma's value of 17.00% is 509.3% above this benchmark. Historically, Marksans Pharma's own Return-on-Tangible-Asset has ranged from 1.40 to 23.95 over the past decade. While the company's 10-year median is 13.41 vs. the industry median of 2.79, Marksans Pharma has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Asset for a Drug Manufacturers company?
The median Return-on-Tangible-Asset among Drug Manufacturers companies is 2.79, based on 1,007 companies in the industry. Companies in the top quartile (top 25%) have a Return-on-Tangible-Asset significantly above this median, while those in the bottom quartile fall well below. However, Return-on-Tangible-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Marksans Pharma's current Return-on-Tangible-Asset of 17.00% is 509.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Asset mean?
A high Return-on-Tangible-Asset can signal that a stock is expensive relative to its fundamentals. Return on tangible assets is the ratio of current-period net income to average two-period tangible assets. View historical data on Marksans Pharma and its competitors. For the Drug Manufacturers industry, the median Return-on-Tangible-Asset is 2.79 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Marksans Pharma's current Return-on-Tangible-Asset is 17.00%, which is 27% above median its own 10-year median of 13.41. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Marksans Pharma stock overvalued right now?
Based on GuruFocus' analysis, Marksans Pharma (BOM:524404) is currently considered Significantly Overvalued. The stock's GF Value™ is ₹253.38, compared to a current price of ₹332.50 — trading 31.2% above its estimated fair value. The current Return-on-Tangible-Asset is 17.00%, which is 27% above median its 10-year median of 13.41 and 509.3% above the Drug Manufacturers industry median of 2.79. Marksans Pharma's overall GF Score™ is 80/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Asset calculated?
Return-on-Tangible-Asset is calculated from a company's financial statements. For Marksans Pharma (BOM:524404), the current Return-on-Tangible-Asset is 17.00% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Marksans Pharma (BOM:524404) Overvalued in 2026?
Based on GuruFocus' analysis, Marksans Pharma stock appears to be overvalued.
The current stock price of ₹332.50 is trading 31.2% above its estimated GF Value™ of ₹253.38.
GuruFocus considers Marksans Pharma to be Significantly Overvalued.
Key valuation signals for BOM:524404:
Return-on-Tangible-Asset: 17.00% (27% above median its 10-year median of 13.41)
GF Value™: ₹253.38 vs. price of ₹332.50 (31.2% above fair value)
Industry Position: 509.3% above the Drug Manufacturers median (#112 of 1007)
No single metric tells the full story. See the BOM:524404 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Marksans Pharma Ltd is a pharmaceutical company. The company is engaged in the research, manufacturing, and marketing of pharmaceutical formulations. It manufactures analgesics, gastroenterology, anti-diabetic, cardiovascular, pain management, gynecology, gastrointestinal, and oncologic drugs as well as antibiotics and antiallergic medications. Geographically, the majority of its revenue is generated from the United States and North America, followed by Europe and the UK, Australia and New Zealand, and the Rest of the World.
80GF Score
Get the complete analysis for BOM:524404
Return-on-Tangible-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BOM:524404 has been successfully added to your 
